Transcription of 5 – Quality (CMC) considerations
{{id}} {{{paragraph}}}
115 Quality (CMC) considerations Presentation to APEC Preliminary Workshop on Review of Drug Development in clinical TrialsCelia Lourenco, PhD,Manager, clinical Group IOffice of clinical TrialsTherapeutic Products DirectorateL1 Slide 1L1 Lourenco; : the information within this presentation is based on the presenter's expertise and experience, and represents the views of the presenter for the purposes of a training workshop3 Overview Objective in the assessment of Quality CMC framework Summary of Quality (CMC) requirements and some deficiencies frequently encountered Guidance documents and templates Exercise4 Overarching ObjectiveEnsure that trial subjects are not placed at risk, and that the results of clinical trials are unaffected by inadequate safety, Quality or efficacy arising from unsatisfactory manufacture5 CMC Framework for clinical Trials Schedule B provides a list of Pharmacopeias Division 5: CMC information in respect of the drug is required i
1 5 – Quality (CMC) considerations Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD,
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
Conducting Cancer Clinical Trials A, Conducting Cancer Clinical Trials, Laws, Regulations and Clinical Trial Agreements, Clinical, Build Risk Management into Clinical, Based Monitoring Strategies for Improved, Based Monitoring Strategies for Improved . Clinical Trial, Clinical trial, Product Lifecycle Management for the, Oracle, Product Lifecycle Management for the Pharmaceutical